|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-3.36/0.39
|
企業價值
9.04M
|
資產負債 |
每股賬面淨值
8.69
|
現金流量 |
現金流量率
--
|
損益表 |
收益
15.20M
|
每股收益
7.46
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/16 03:04 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologistsin many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers. |